ISSN: 1522-4821

Revista internacional de salud mental de emergencia y resiliencia humana

Acceso abierto

Nuestro grupo organiza más de 3000 Series de conferencias Eventos cada año en EE. UU., Europa y América. Asia con el apoyo de 1.000 sociedades científicas más y publica más de 700 Acceso abierto Revistas que contienen más de 50.000 personalidades eminentes, científicos de renombre como miembros del consejo editorial.

Revistas de acceso abierto que ganan más lectores y citas
700 revistas y 15 000 000 de lectores Cada revista obtiene más de 25 000 lectores

Abstracto

Most Common Side Effects of Clozapine and Their Management

Mohammad Masud Iqbal, Shivale Swati, Alka Aneja, Mohammad Touhid Iqbal, Esha Aneja and Sumala Haque

Clozapine is a novel, unique and oldest second generation (atypical) antipsychotic agent, first introduced in 1970s in the European market in under trade name, Leponex but has been withdrawn years in 1974 due to development of severe neutropenia (agranulocytosis) resulting in cluster of deaths. It was reintroduced in the early 1990s in United States under trade name, Clozaril by U.S. Food and drug Administration (FDA) for use in treatment resistant schizophrenia in adults and for reduction of risk of persistent suicidal ideation or aggressive behavior in schizophrenic patients. As of today, Clozapine remains the most effective antipsychotic available in reducing both positive and negative symptoms in patients with schizophrenia who fail to respond to typical antipsychotic agent, treating affective disorders, some neurological disorders, aggression, as well as psychosis in patients with dementia and parkinsonism. Most side effects associated with clozapine in general are typically benign, tolerable, and manageable.